Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01143974

Enrollment

Registered

2010-06-15

Start date

2010-06-30

Completion date

2012-06-30

Last updated

2013-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Malignant Neoplasm

Keywords

progress free survival, response rate, safety

Brief summary

For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer. The combination of these two drug may have a synergy with each other in treatment of advanced breast cancer.

Detailed description

combination of pemetrexed and cisplatin to treat advanced breast cancer. Previous regimen no more than 3 which including enthrycycline and taxanes(paclitaxel and/or docetaxel)

Interventions

DRUGpemetrexed plus cisplatin

pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* 18-70 years old * Resistant to enthracycle and taxanes * Has measurable disease

Exclusion criteria

* Has more than 3 previous chemotherapy regimens

Design outcomes

Primary

Measure	Time frame
PFS (progression free survival)	2 Years

Secondary

Measure	Time frame	Description
Safety	2 years	Assessing for Hematology and Non-hematology toxicities, including all SAEs.
Response Rate	2 years	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026